HYBIO(SZ:300199) Zheng Quan Shi Bao Wang·2025-10-29 11:44Core Viewpoint - Han Yu Pharmaceutical (300199) reported a significant increase in revenue for the first three quarters of 2025, driven by a rise in formulation income, despite a net loss in the third quarter [1] Financial Performance - The company's third-quarter revenue reached 134 million yuan, marking an 11.86% year-on-year increase [1] - The net loss for the third quarter was 74.12 million yuan, compared to a loss of 24.44 million yuan in the same period last year [1] - For the first three quarters of 2025, total revenue was 683 million yuan, reflecting an 82.06% year-on-year growth [1] - The net profit for the first three quarters was 71.35 million yuan, a turnaround from a loss of 34.81 million yuan in the previous year [1] - Basic earnings per share for the first three quarters stood at 0.08 yuan [1]